Cleviprex (Clevidipine Butyrate) Patent Expiration, LOE Window & CMS Spending

Cleviprex (Clevidipine Butyrate) by Chiesi Usa: FDA Orange Book LOE 2031-10-10, 0 AB generics, $163K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorChiesi Usa
FDA Application & PathwayN022156 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-10-10
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$163K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$163K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 11.4% 2-yr change)